Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr Tarantino on the Safety of T-DXd and T-DM1 in HER2+ Breast Cancer

July 2nd 2024

Paolo Tarantino, MD, discusses updated safety data from the phase 3 DESTINY-Breast03 trial of T-DXd in HER2+ breast cancer.

Dr Davis on the Potential For ADCs to Continue to Reshape Breast Cancer Treatment

July 2nd 2024

Andrew Davis, MD, discusses how antibody-drug conjugates could continue to reshape the breast cancer treatment paradigm.

Dual mTORC1/mTORC2 Inhibitor Sapanisertib Shows Promise in Combination Regimens for Solid Tumors

July 2nd 2024

Vivek Subbiah, MD, details the rationale for combining sapanisertib with ziv-aflibercept or metformin and next steps for mTOR inhibitors in solid tumors.

Case Presentation 1: PIK3CA Mutation With ESR1 Mutations

July 1st 2024

Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, present a patient case involving a 54-year-old postmenopausal woman diagnosed with a 2.1cm estrogen receptor positive (ER+), HER2 negative breast cancer, and discuss the clinical implications and management strategies for this specific patient scenario.

Dynamics of ESR1 Alterations and Serial Liquid Biopsies

July 1st 2024

In their discussion, medical experts in the field of breast cancer explore the role of liquid biopsies and compare the significance of ESR1 mutations to other biomarkers, such as PIK3CA, in terms of their driver versus passenger status in the context of HR+/HER2- breast cancer.

Clinical Impact of Subcutaneous Fixed-Dose Pertuzumab – trastuzumab-hyaluronidase in HER2+ Breast Cancer

July 1st 2024

Breast cancer specialists outline their institution’s practices regarding the choice between subcutaneous fixed-dose pertuzumab – trastuzumab-hyaluronidase and intravenous pertuzumab and trastuzumab.

Preoperative Monitoring and Surgical Options for HER2+ Patients

July 1st 2024

Kandace P. McGuire, MD, provides clinical insights on how patient monitoring practices inform discussions around surgical options, providing the potential for deescalating surgical management.

Expert Perspectives on Optimizing Biomarker Testing in Advanced HR+/HER2- Breast Cancer

July 1st 2024

A panel of experts give perspectives on optimizing biomarker testing in Advanced HR+/HER2- Breast Cancer.

Advancements in Adjuvant Therapy in Early-Stage HR+ Breast Cancer

July 1st 2024

A panel of experts discuss advancements in adjuvant therapy for early-stage breast cancer.

postMONARCH Meets Primary End Point of Improvement of PFS in HR+/HER2– Breast Cancer Post–CDK4/6i Progression

June 29th 2024

Kevin Kalinsky, MD, MS, discusses the outcomes of the postMONARCH study in patients with HR+/HER2– breast cancer following disease progression.

Dr Mouabbi on the Use of Ribociclib vs Abemaciclib in HR+/HER2– Breast Cancer

June 28th 2024

Jason Abdou Mouabbi, MD, discusses considerations for the use of ribociclib vs abemaciclib in patients with HR-positive, HER2-negative breast cancer.

Dr Llombart-Cussac on Preventing Neutropenia and Diarrhea in HR+/HER2– Advanced Breast Cancer

June 28th 2024

Antonio Llombart-Cussac, MD, PhD, discusses preventing neutropenia and diarrhea with sacituzumab govitecan in HR+/HER2– advanced breast cancer.

FDA Approves Tepylute for Breast and Ovarian Cancer Treatment

June 28th 2024

The FDA has approved a new drug application for Tepylute, a ready-to-dilute formulation to treat breast and ovarian cancers.

Dr O'Shaughnessy on MammaPrint H1 vs H2 Status on 3-year RFS in HR+, HER2– Breast Cancer

June 27th 2024

Joyce O'Shaughnessy, MD, on the impact of MammaPrint H1 and H2 status on 3-year relapse-free survival in HR-positive, HER2-negative early breast cancer.

Dr Waks on Unmet Needs in Patients With HER2+ Breast Cancer

June 26th 2024

Adrienne G. Waks, MD, discusses efforts to address unmet needs in HER2-positive breast cancer.

Dr Rimm on Unmet Needs in Distinguishing Between HER2-Low and HER2-Ultralow Breast Cancer

June 26th 2024

David Rimm, MD, PhD, discusses challenges in distinguishing between HER2-low and HER2-ultralow breast cancer using current diagnostic kits.

Intrathecal Dendritic Cells Under Evaluation for Leptomeningeal Disease in TNBC and HER2+ Breast Cancer

June 26th 2024

Peter Forsyth, MD, on the investigation of intrathecal dendritic cells for leptomeningeal disease in triple-negative and HER2-positive breast cancer.

Biomarker Testing Best Practices in HR+/HER2- Locally Advanced or Metastatic Breast Cancer

June 26th 2024

Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, delve into the most clinically significant genomic tests and biomarker assays employed in HR+/HER2- breast cancer, focusing on BRCA mutations, PIK3CA alterations, AKT1 alterations, and PTEN alterations, which play crucial roles in determining prognosis and guiding treatment decisions.

First-Line Treatment Options in HR+/HER2- Locally Advanced and Metastatic Breast Cancer and Challenges with Treatment Resistance

June 26th 2024

Medical experts share their strategies for choosing initial treatment options for HR+/HER2- locally advanced or metastatic breast cancer, debating the most effective frontline therapies based on clinical trial evidence, while also discussing their aspirations for a new standard of care, and the challenges of managing disease progression.

Trastuzumab Deruxtecan (T-DXd) vs Physician’s Choice of Chemotherapy (TPC) in Patients (pts) With Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low or HER2-Ultralow Metastatic Breast Cancer (mBC) With Prior Endocrine Therapy (ET): Primary Results From DESTINY-Breast06 (DB-06)

June 25th 2024

Dr. Aditya Bardia presents the findings of DESTINY-Breast06 (NCT04494425) in chemotherapy naive patients with HER2-low and HER2-ultra low metastatic breast cancer demonstrating progression-free survival of trastuzumab deruxtecan compared to chemotherapy treatment of physician’s choice.